Volumetric fluid analysis of fixed monthly anti-VEGF treatment in patients with neovascular age-related macular degeneration
Authors:
- 18 June 2023
- journal article
- research article
- Published by Press of International Journal of Ophthalmology (IJO Press) in International Journal of Ophthalmology
- Vol. 16 (6) , 909-914
Abstract
? AIM: To evaluate visual outcomes and changes in fluid after administering monthly anti-vascular endothelial growth factor (VEGF) injections to treat neovascular age -related macular degeneration (nAMD) with subretinal fluid (SRF) and pigment epithelial detachment (PED).? METHODS: This prospective study included eyes with nAMD previously treated with as-needed anti-VEGF injections. The patients were treated with six monthly intravitreal injections of ranibizumab. Quantitative volumetric segmentation analyses of the SRF and PED were performed. The main outcome measures included best-corrected visual acuity (BCVA), and SRF and PED volumes.? RESULTS: Twenty eyes of 20 patients were included in this study. At the 6-month follow-up, BCVA and PED volume did not change significantly (P=0.110 and 0.999, respectively) but the mean SRF volume decreased from 0.53 & PLUSMN;0.82 mm3 at baseline to 0.08 & PLUSMN;0.23 mm3 (P=0.002). The absorption rate of the SRF volume was negatively correlated with the duration of previous anti-VEGF treatment (P=0.029). Seven of the 20 eyes (35%) showed a fluid-free macula and significant improvement in BCVA (P=0.036) by month 6.? CONCLUSION: Quantifying the SRF can precisely determine the patient's responsiveness to anti-VEGF treatment of nAMD.Keywords
This publication has 22 references indexed in Scilit:
- Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degenerationBritish Journal of Ophthalmology, 2016
- Super-dose Anti-VEGF (SAVE) Trial: 2.0 mg Intravitreal Ranibizumab for Recalcitrant Neovascular Macular Degeneration–Primary End PointOphthalmology, 2013
- Three-Dimensional Segmentation of Fluid-Associated Abnormalities in Retinal OCT: Probability Constrained Graph-Search-Graph-CutIEEE Transactions on Medical Imaging, 2012
- PHARMACOKINETIC RATIONALE FOR DOSING EVERY 2 WEEKS VERSUS 4 WEEKS WITH INTRAVITREAL RANIBIZUMAB, BEVACIZUMAB, AND AFLIBERCEPT (VASCULAR ENDOTHELIAL GROWTH FACTOR TRAP-EYE)Retina, 2011
- Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?British Journal of Ophthalmology, 2011
- Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisationBritish Journal of Ophthalmology, 2011
- Is There Tachyphylaxis to Intravitreal Anti-Vascular Endothelial Growth Factor Pharmacotherapy in Age-Related Macular Degeneration?Ophthalmology, 2008
- Time Course of Morphologic Effects on Different Retinal Compartments after Ranibizumab Therapy in Age-related Macular DegenerationOphthalmology, 2008
- Quantitative Subanalysis of Optical Coherence Tomography after Treatment with Ranibizumab for Neovascular Age-Related Macular DegenerationInvestigative Ophthalmology & Visual Science, 2008
- Simultaneous Inference in General Parametric ModelsBiometrical Journal, 2008